
David Schachter
Get their honest, personalized take on your startup.
Sign in to pitch David →At a glance
- Full Name
- David Schachter
- Title
- President
- Firm
- Reedland Capital Partners
- Firm Type
- Boutique investment bank / corporate debt & private equity advisory (securities offered through Weild & Co., FINRA/SIPC). *Note: the supplied stub labeled him an "Angel Investor" — verified sources do not support this. He is an investment banker who structures and arranges institutional debt and equity for middle-market and emerging-growth companies, not an individual angel writing seed checks.*
- Investment Stage
- Middle-market and emerging-growth companies (growth capital, recapitalizations, refinancings, minority equity placements) — not seed-stage angel investing
- Check Size
- Representative transactions ~$11.5M–$165M; debt financings typically $20M–$150M
- Target Company Profile
- Privately held and publicly traded middle-market / emerging-growth firms seeking debt or minority equity capital for acquisitions, growth, dividend recaps, or refinancings
- Sector Focus
- Cross-industry (15+ sectors) — biotech, medical devices, technology/IT, wireless & satellite communications, clean tech, defense, media, education, consumer/e-commerce, transportation & logistics
- Geographic Focus
- United States (nationwide)
- Location
- Mill Valley, California (30 Sunnyside Avenue, Mill Valley, CA 94941)
Background
David Schachter is President of Reedland Capital Partners, a boutique investment bank based in Mill Valley, California, that structures and arranges institutional debt and equity financings for middle-market and emerging-growth companies. He heads the firm's corporate debt and private equity advisory groups and is described on the firm's site as "a nationally recognized expert" in middle-market corporate debt and equity transactions over the past 30 years, with deep experience structuring, arranging, and negotiating complex financings and helping companies optimize their capital structures.
Before moving into investment banking, Schachter practiced law for more than 12 years as a securities and financial-institutions transactional attorney. He began at Pillsbury, Madison & Sutro (a major San Francisco-founded law firm, now Pillsbury Winthrop Shaw Pittman) and later became a partner at a boutique Los Angeles firm specializing in representing financial institutions and real estate developers. His legal work spanned loan workouts, commercial real estate transactions, and complex equity and debt financings — a foundation directly relevant to his current advisory practice.
He holds an M.B.A. in Corporate Finance from the University of San Diego School of Business (magna cum laude) and a J.D. from the USD School of Law (cum laude, and a member of the USD Law Review). He is a licensed General Securities Principal (Series 24) and General Securities Representative (Series 7). Reedland Capital Partners, founded in 1997, has advised on billions of dollars of transactions across a wide range of industries; securities are offered through Weild & Co.
Investment Thesis & Focus
- Acts as a financial advisor / placement agent, not a fund principal — Reedland arranges third-party institutional debt and equity rather than investing off its own balance sheet.
- Focuses on middle-market and emerging-growth companies across most industries, including healthcare/biotech, medical devices, IT and software, wireless and satellite technology, defense, clean technology, media, education, transportation/logistics, consumer, and e-commerce.
- Debt advisory practice targets financings roughly $20M–$150M for acquisitions, growth capital, dividend recapitalizations, or refinancing existing debt on more favorable terms.
- Equity practice raises minority growth capital for privately held companies and financings for publicly traded issuers.
- Firm's stated positioning: it specializes in "structuring and arranging institutional debt and equity financings" and in helping companies "optimize their capital structures for improved profitability."
Notable Investments
- Rubicon Technologies (NYSE: RBT) — waste/recycling tech; Reedland served as financial advisor on a ~$165M equity transaction and placement agent on a separate ~$21M raise.
- Renibus Therapeutics — clinical-stage biotech; ~$30M financing (a conventional debt round reported around August 2022).
- Valeo Pharma (TSX: VPH) — specialty pharmaceuticals; ~$40M as financial advisor.
- Synergy CHC (NASDAQ: SNYR) — consumer health; ~$20M equity advisory.
- ECA Medical Instruments — single-use surgical/medical devices; ~$16M equity.
- Auterion — drone/autonomous software; senior credit facility (debt advisory).
- Havah Therapeutics — women's health biotech; Reedland acted as general advisor (~2026).
- Historical / larger deals cited by the firm include Dendreon (~$130M), Medivation (~$100M), Onyx Pharmaceuticals (~$150M), and Globalstar (~$105M) in biotech and satellite communications.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.